Vaxcyte, Inc. PCVX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s additional paid-in capital?
- Vaxcyte, Inc. (PCVX) reported additional paid-in capital of $5.48B in Q1 2026.
- How has Vaxcyte, Inc.'s additional paid-in capital changed year-over-year?
- Vaxcyte, Inc.'s additional paid-in capital increased by 15.8% year-over-year, from $4.73B to $5.48B.
- What is the long-term trend for Vaxcyte, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s additional paid-in capital has grown at a 54.8% compound annual growth rate (CAGR), from $544.35M to $4.84B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.